SURROZEN INC (SRZN)
Health Care · biotechnology · NASDAQ
A clinical-stage biotechnology company leveraging its proprietary Wnt pathway modulation platform to develop innovative, tissue-selective therapeutics for serious ophthalmic diseases.
What SURROZEN INC does
Surrozen is a biotechnology company focused on the development of antibody-based therapeutics that modulate the Wnt signaling pathway for the treatment of serious eye diseases. The company's platform designs tissue-selective therapies to restore tissue structure and function in indications like diabetic macular edema and wet age-related macular degeneration. Its lead candidates, including SZN-8141 and SZN-8143, are engineered to combine Wnt pathway activation with other mechanisms like VEGF antagonism to address unmet needs in ophthalmology.
Recent developments
On October 2, 2026, the company received FDA clearance for its IND application for SZN-8141, triggering a $95.1 million milestone payment from a private placement that closed on October 20, 2026. This financing extended the company's cash runway into 2029 to support the DUET Phase 1b/2a clinical trial of SZN-8141 and the advancement of its ophthalmology pipeline.
From SURROZEN INC's filing of 2026-10-20.
Themes: ophthalmology, tissue regeneration, Wnt signaling pathway, retinal vascular diseases
Fundamentals
- Price$25.14 as of 2026-10-20 close
- Market cap$295M as of 2026-08-04 (share count; price 2026-10-20)
- 1-year return+82.3% 2025-10-20 close $13.79 → 2026-10-20 close $25.14
- P/En/a negative earnings
- Net margin-6960.8% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-67.4% FY2025, SEC XBRL
- Beta0.67 as of 2026-09-02
- Last reported earnings2026-10-20 SEC EDGAR Form 8-K (Item 2.02)
How SRZN compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $5M | -$10M | $50M | -$0.41 | -$7M† | $19000† |
| Q1 FY2026 2026-03-31 | $5M | -$10M | -$128M | -$11.65 | -$12M | $120000 |
| Q4 FY2025 2025-12-31 | $528000† | -$13M† | -$183M† | -$23.88† | -$6M† | $59000† |
| Q3 FY2025 2025-09-30 | $983000 | -$11M | -$72M | -$8.36 | -$9M† | $24000† |
| Q2 FY2025 2025-06-30 | $983000 | -$9M | $40M | $2.55 | -$6M† | $18000† |
| Q1 FY2025 2025-03-31 | $983000 | -$10M | -$27M | -$7.43 | -$9M | $27000 |
| Q4 FY2024 2024-12-31 | $655000† | -$9M† | -$28M† | -$9.10† | $3M† | $19000† |
| Q3 FY2024 2024-09-30 | $10M | $1M | -$1M | -$0.44 | -$7M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$102M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How SURROZEN INC looks technically
SURROZEN INC (SRZN) is trading 1.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 47 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day high about 19 trading days ago. It is 33.5% below its highest point of the past year. Trading volume is unusually light — only about 37% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 1.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.71 | $23.71 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.71 | $24.71 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 21.85. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 47 trading days ago — a "death cross", a bearish long-term signal | 47 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.7% above | +1.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 30.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 50.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.85 to $32.00) — its "stochastic" reading is 32 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 32.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $37.83 | $37.83 |
|---|---|---|
| From the 52-week high | it is 33.5% below its 52-week high (its highest price of the past year) | -33.5% |
| Above the 52-week low | it is 120.7% above its 52-week low (its lowest price of the past year) | +120.7% |
| Below the 52-week high | it is 33.5% below its highest point of the past year | 33.5% |
| Since a 20-day breakout | it made a new 20-day high about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $208.96 (set on 2021-09-17) | $208.96 |
| Given back of the 52-week move | over the past year its closes ranged ($11.80 to $34.13), and it has given back roughly a third of its rise from last year’s low — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.62 to $20.33. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.3% |
| From the all-time high | it is 88.0% below its all-time high | -88.0% |
| Nearest price level | it is sitting right on a support level at $25.02 — a price it turned at three times since 2025-12-12, most recently on 2026-05-20. Since 2024-10-21 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $4.48 (set on 2023-11-09) | $4.48 |
| Above the all-time low | it is 461.5% above its all-time low | +461.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 85% of the past ~6 months) | 85th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.81 between its high and its low — about 11.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.81 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.07 and $34.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.07 – $27.02 – $34.96 |
| Typical daily range (% of price) | its price moves about 11.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.2% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (1.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 37% of its 30-day average | 0.37× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 89.1% above the previous close 18 sessions ago and has not traded back through the level it left behind at 16.16 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +89.1% |
| Gap filled | a 2.9% gap down opened on 2026-10-13 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.25% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 50.9 percentage points (the stock gained 51.9% while the market gained 1.0%) | +50.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.8 percentage points (the stock gained 13.4% while the market gained 3.6%) | +9.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.6 percentage points (the stock lost 22.0% while the market gained 8.5%) | -30.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 67.7 percentage points (the stock gained 82.3% while the market gained 14.6%) | +67.7% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.1% of the share price. | +11.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $27.05 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -7.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $28.75 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -12.6% |
Price levels it has turned at before
SRZN last closed at $25.14 on 2026-10-20. Since 2024-10-21 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.02 | Support | 0.5% below the last close | turned there three times · 2025-12-12 to 2026-05-20 |
| $23.45 | Support | 6.7% below the last close | turned there five times · 2026-02-26 to 2026-09-08 |
| $27.05 | Resistance | 7.6% above the last close | turned there three times · 2026-04-27 to 2026-08-07 |
| $18.14 | Support | 27.8% below the last close | turned there twice · 2025-01-03 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $21.85.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $43.54 and $56.94 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $21.85.
This reading has stood for 1 trading day, since 2026-10-20.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$48.40 range $40.00 – $54.00; median $52.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SRZN
- Consensus EPS estimate-$1.32 next reporting period, as of 2026-10-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant losses with no regulatory-approved products and uncertainty of future profitability.","Requirement for substantial additional capital to fund the research, clinical development, and commercialization of product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of SRZN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 annual report filed March 23, 2026; older filing references 2024 annual report filed March 31, 2025
- Newer filing states SZN-8141 'anticipates submitting an IND for SZN-8141 in the second half of 2026'
- Newer filing describes SZN-8143 as combining 'Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6, antagonism' for treatment of 'DME, wet AMD, and uveitic macular edema, or UME'
- Newer filing includes research programs section describing corneal endothelial disease and retinal research models without specific product candidate designation
- Newer filing specifies 'localized delivery enables controlled therapeutic modulation' for ophthalmology approach
- Removed:
- Older filing stated strategic focus on discovering candidates for 'a broad range of organs and tissues' and listed diseases in intestine, liver, lung, kidney, cochlea, skin, pancreas and central nervous system
- Older filing contained language 'we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics'
- Older filing stated SZN-8141 nominated 'in the third quarter of 2024' and expected to 'file an Investigational New Drug application and commence clinical studies for SZN-8141 in 2026'
- Older filing stated SZN-8143 nominated 'in the third quarter of 2024'
- Older filing included dedicated section on 'SZN-113 for Fuchs' Endothelial Corneal Dystrophy and Geographic Atrophy' as a development candidate targeting Fzd127
- Reworded:
- Newer: 'product candidates to selectively modulate the Wnt pathway'; Older: 'drug candidates to selectively modulate the Wnt pathway'
- Newer: 'our current strategic focus is ophthalmology'; Older: 'current focus in ophthalmology'
- Newer: mission 'transform the treatment of serious ophthalmic disease'; Older: 'transform the treatment of serious disease'
- Newer: 'restoration of tissue structure and function in serious eye diseases'; Older: referred to 'severe diseases' across multiple organs
- Newer describes SZN-8141 as combining Fzd4 and VEGF with potential over 'single mechanism agents'; Older: 'single agents'
- Newer: 'retinopathy indications'; Older: 'retinal vascular diseases'
- Newer: research programs section describes potential without specific candidate naming; Older: SZN-113 was explicitly named development candidate
- Notes:
- The newer MD&A appears truncated mid-sentence at 'SZN-413 for Retinal Diseases' section, limiting full comparison of that subsection
- Older filing text also appears truncated at end of SZN-413 section
- Strategic shift from multi-indication approach to ophthalmology-focused approach is evident but text does not explicitly state discontinuation of non-ophthalmic programs
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 5 sells ($7M) — 4 selling insiders
Most recent open-market transaction: 2026-07-22. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SRZN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding SRZN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 540,670
- Reported value $14,030,387
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SRZN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SRZN had 2,189,760 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
SRZN had 18.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.51 days to cover at the same settlement.
- Reported short interest (shares) 2,189,760
- Short interest (% of shares outstanding) 18.6%
- Prior settlement (shares) 2,195,505
- Reported change -0.26%
- Days to cover (reported) 1.51
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (Vabysmo)
- Regeneron (Eylea)
- Merck (remigromig)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
SURROZEN INC is found in…
Frequently asked questions
What does SURROZEN INC (SRZN) do?
Surrozen is a biotechnology company focused on the development of antibody-based therapeutics that modulate the Wnt signaling pathway for the treatment of serious eye diseases. The company's platform designs tissue-selective therapies to restore tissue structure and function in indications like diabetic macular edema and wet age-related macular degeneration.
What sector is SURROZEN INC (SRZN) in?
SURROZEN INC (SRZN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are SURROZEN INC's (SRZN) competitors?
Notable peers of SURROZEN INC (SRZN) include Roche (Vabysmo), Regeneron (Eylea) and Merck (remigromig). This peer set is informational only — not financial advice.
Is SURROZEN INC (SRZN) overbought or oversold right now?
SURROZEN INC (SRZN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SRZN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.